Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 2

Conditions

Sarcoma 727Glioblastoma 354Gliosarcoma 341Brain Neoplasms 254Central Nervous System Neoplasms 223Astrocytoma 204Osteosarcoma 202Gastrointestinal Stromal Tumors 176Dendritic Cell Sarcoma, Interdigitating 174Glioma 165Lymphoma 163Burkitt Lymphoma 162Precursor Cell Lymphoblastic Leukemia-Lymphoma 158Neoplasms 155Lymphoma, Non-Hodgkin 151Oligodendroglioma 147Recurrence 138Lymphoma, Large B-Cell, Diffuse 133Neuroblastoma 130Lymphoma, Follicular 127Breast Neoplasms 121Leukemia, Lymphocytic, Chronic, B-Cell 120Lymphoma, Mantle-Cell 119Leukemia 116Lymphoma, B-Cell, Marginal Zone 113Lymphoma, Large-Cell, Immunoblastic 112Rhabdomyosarcoma 111Hodgkin Disease 110Bone Neoplasms 109Sarcoma, Kaposi 102

Interventions

Sorafenib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Recurrent Uterine Sarcoma × Sarcoma × Clear all
NCT00075400 2019-07-24

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

NCT00238121 2015-11-20

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡